uniQure N.V.
AMT-130
Huntington’s disease
Date
TBD
FDA decision · Date TBD estimated
What's at stake
An FDA complete response letter on AMT-130 for Huntington’s disease is in focus around Date TBD.
Primary source
· SEC 8-K
verified 13h ago
“The risk that the FDA ultimately concludes that the Phase I/II trial data are not sufficient to support a BLA or accelerated approval”